Brief: Glenmark Pharmaceuticals Inc., USA Launches Sugammadex Injection, 200 Mg/2 Ml & 500 Mg/5 Ml Single-Dose Vials
28/07/2026 19:54
BRIEF-Glenmark Pharmaceuticals Inc., USA Launches Sugammadex Injection, 200 Mg/2 Ml & 500 Mg/5 Ml Single-Dose Vials July 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMACEUTICALS INC., USA LAUNCHES SUGAMMADEX INJECTION, 200 MG/2 ML (100 MG/ML) AND 500 MG/5 ML (100 MG/ML) SINGLE-DOSE VIALS
Source text: ID:nPn4nCtCka
Further company coverage: GLEN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter